Stephanie Dias

Ms. Stephanie Dias

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
NMNompumelelo Malaza
Nompumelelo Malaza
MMMatladi Masete
Matladi Masete
Sumaiya AdamSumaiya Adam
Sumaiya Adam
SDStephanie Dias
Stephanie Dias
TNThembeka Nyawo
Thembeka Nyawo
CPCarmen Pheiffer
Carmen Pheiffer
Pregestational type 1 (T1DM) and type 2 (T2DM) diabetes mellitus and gestational diabetes mellitus (GDM) are associated with increased rates of adverse maternal and neonatal outcomes. Adverse outcomes are more common in women with pregestational diabetes compared to GDM; although, conflicting results have been reported. This systematic review aims to summarise and synthesise studies that have compared adverse pregnancy outcomes in pregnancies complicated by pregestational diabetes and GDM. Three databases, Pubmed, EBSCOhost and Scopus were searched to identify studies that compared adverse outcomes in pregnancies complicated by pregestational T1DM and T2DM, and GDM. A total of 20 studies met the inclusion criteria and are included in this systematic review. Thirteen pregnancy outcomes including caesarean section, preterm birth, congenital anomalies, pre-eclampsia, neonatal hypoglycaemia, macrosomia, neonatal intensive care unit admission, stillbirth, Apgar score, large for gestational age, induction of labour, respiratory distress syndrome and miscarriages were compared. Findings from this review confirm that pregestational diabetes is associated with more frequent pregnancy complications than GDM. Taken together, this review highlights the risks posed by all types of maternal diabetes and the need to improve care and educate women on the importance of maintaining optimal glycaemic control to mitigate these risks.

Verified
Journal Article
Open access
PDF file
SDStephanie Dias
Stephanie Dias
CPCarmen Pheiffer
Carmen Pheiffer
YAYoonus Abrahams
Yoonus Abrahams
PRPaul Rheeder
Paul Rheeder
Sumaiya AdamSumaiya Adam
Sumaiya Adam
Gestational diabetes mellitus (GDM) is a growing public health problem worldwide. The condition is associated with perinatal complications and an increased risk for future metabolic disease in both mothers and their offspring. In recent years, molecular biomarkers received considerable interest as screening tools for GDM. The purpose of this review is to provide an overview of the current status of single-nucleotide polymorphisms (SNPs), DNA methylation, and microRNAs as biomarkers for GDM. PubMed, Scopus, and Web of Science were searched for articles published between January 1990 and August 2018. The search terms included “gestational diabetes mellitus”, “blood”, “single-nucleotide polymorphism (SNP)”, “DNA methylation”, and “microRNAs”, including corresponding synonyms and associated terms for each word. This review updates current knowledge of the candidacy of these molecular biomarkers for GDM with recommendations for future research avenues.

19 March 2018 in Molecular Diagnosis & Therapy
Verified
Journal Article
Closed access
PDF file
CPCarmen Pheiffer
Carmen Pheiffer
SDStephanie Dias
Stephanie Dias
PRPaul Rheeder
Paul Rheeder
SASumaiya Adam
Sumaiya Adam

6 April 2018 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
PDPhiwayinkosi V. Dludla
Phiwayinkosi V. Dludla
SDStephanie Dias
Stephanie Dias
NONnini Obonye
Nnini Obonye
Rabia JohnsonRabia Johnson
Rabia Johnson
JLJohan Louw
Johan Louw
BNBongani B. Nkambule
Bongani B. Nkambule

Verified
Journal Article
Open access
PDF file
CPCarmen Pheiffer
Carmen Pheiffer
SDStephanie Dias
Stephanie Dias
BJBabalwa Unice Jack
Babalwa Unice Jack
NMNompumelelo Malaza
Nompumelelo Malaza
Sumaiya AdamSumaiya Adam
Sumaiya Adam
Adiponectin is an adipocyte-derived hormone that plays a critical role in energy homeostasis, mainly attributed to its insulin-sensitizing properties. Accumulating studies have reported that adiponectin concentrations are decreased during metabolic diseases, such as obesity and type 2 diabetes, with an emerging body of evidence providing support for its use as a biomarker for pregnancy complications. The identification of maternal factors that could predict the outcome of compromised pregnancies could act as valuable tools that allow the early recognition of high-risk pregnancies, facilitating close follow-up and prevention of pregnancy complications in mother and child. In this review we consider the role of adiponectin as a potential biomarker of disorders associated with pregnancy. We discuss common disorders associated with pregnancy (gestational diabetes mellitus, preeclampsia, preterm birth and abnormal intrauterine growth) and highlight studies that have investigated the potential of adiponectin to serve as biomarkers for these disorders. We conclude the review by recommending strategies to consider for future research.

31 August 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
SDStephanie Dias
Stephanie Dias
CPCarmen Pheiffer
Carmen Pheiffer
Sumaiya AdamSumaiya Adam
Sumaiya Adam
Gestational diabetes mellitus (GDM) is a growing public health concern that affects many pregnancies globally. The condition is associated with adverse maternal and neonatal outcomes including gestational hypertension, preeclampsia, placental abruption, preterm birth, stillbirth, and fetal growth restriction. In the long-term, mothers and children have an increased risk of developing metabolic diseases such as type 2 diabetes and cardiovascular disease. Accumulating evidence suggest that alterations in the maternal microbiome may play a role in the pathogenesis of GDM and adverse pregnancy outcomes. This review describes changes in the maternal microbiome during the physiological adaptations of pregnancy, GDM and adverse maternal and neonatal outcomes. Findings from this review highlight the importance of understanding the link between the maternal microbiome and GDM. Furthermore, new therapeutic approaches to prevent or better manage GDM are discussed. Further research and clinical trials are necessary to fully realize the therapeutic potential of the maternal microbiome and translate these findings into clinical practice.